Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,706 followers
Hemolysis ratio (%) = (A A n )/(A p A n ) 100%, where A represents the absorbance value for the sample group, A p represents the absorbance value for the positive group and A n is the absorbance value for the negative group
N Engl J Med 382(20):19261932
Accordingly, the absolute levels of GSH were increased in isolated mitochondria (gated as shown in Supplementary Fig
7.3 2.9 ng/ml)
Availability: In stock Research Applications Common Use A common use for Ipamorelin 10MG is in research on growth hormone release and endocrine function
